Why high-tech patent expertise will be increasingly valued by life sciences companies
If the experience of NantWorks’ IP chief Mark Kokes is anything to go by, leading strategists from other sectors can make a splash in pharma and biotech
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.